OncoMatch/Clinical Trials/NCT05892393
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Is NCT05892393 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Zirconium Zr 89-DFO-YS5 for multiple myeloma.
Treatment: Zirconium Zr 89-DFO-YS5 — This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Lab requirements
Kidney function
Creatinine clearance >= 60 mL/min, calculated using the Cockcroft-Gault equation or serum creatinine <= 1.5x the institutional upper limit of normal
Liver function
Total bilirubin <= 1.5 X institutional upper limit of normal (ULN); AST <= 3 X ULN; ALT <= 3 X ULN
Total bilirubin <= 1.5 X institutional upper limit of normal (ULN); AST <= 3 X ULN; ALT <= 3 X ULN; Creatinine clearance >= 60 mL/min, calculated using the Cockcroft-Gault equation or serum creatinine <= 1.5x the institutional upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify